• In-depth knowledge in Alzheimer' s disease, Parkinson's disease and Multiple Sclerosis and extensive R&D experience with in vitro and in vivo disease modeling, genetic intervention, target protease modulation and quantitative beta-/gamma secretase activity assays;
• in-vitro/ex-vivo bioassay development and validation for reliable, robust beta-/gamma-secretase inhibitor screening; hands-on expertise in efficacy and mechanism assessment by using multiple technology platforms, such as knock-in / knock-out cell based assay/modeling, ELISA, immuno-PCR, q-RT-PCRs, primary embryonic neuron/glia preparation and cultures for cellular modeling, HT functional genomic screening of siRNA/shRNA libraries, 1D/2DWestern blotting and quantitative 2D-DIGE, and IHC.
1. Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP Transgenic Mice. McConlogue L1, Buttini M, Anderson JP, Brigham EF, Chen KS, Freedman SB, Games D, Johnson-Wood K, Lee M, Zeller M, Liu W, Motter R, Sinha S. J Biol Chem. 2007 Sep 7;282(36):26326-34.
2. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Roberds SL1, Anderson J, Basi G, Bienkowski MJ, Branstetter DG, Chen KS, Freedman SB, Frigon NL, Games D, Hu K, Johnson-Wood K, Kappenman KE, Kawabe TT, Kola I, Kuehn R, Lee M, Liu W, Motter R, Nichols NF, Power M, Robertson DW, Schenk D, Schoor M, Shopp GM, Shuck ME, Sinha S, Svensson KA, Tatsuno G, Tintrup H, Wijsman J, Wright S, McConlogue L; Hum Mol Genet. 2001 Jun 1;10(12):1317-24.